Clinical Trials Logo

Filter by:
NCT ID: NCT05652543 Completed - COVID-19 Pandemic Clinical Trials

A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine

SCTV01E
Start date: January 5, 2023
Phase: Phase 2
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the safety and immunogenicity of SCTV01E in population of different ages who have been vaccinated against COVID-19. A total of 750 participants ≥3 years old who have received the recommended dose and immunization procedure of domestically approved COVID-19 vaccines will be enrolled, including 250 participants ≥18 years old (group A), 250 participants aged 12-17 years old (group B), and 250 participants aged 3-11 years old (group C). The study will be carried out gradually according to the age of the participants from older to younger. Considering that SCTV01E in this study is the first clinical study in participants under 18 years old, 15 sentinel participants will be assigned to group B and 30 sentinel participants will be assigned to group C (including 15 aged 6-11 years old and 15 aged 3-5 years old). The Primary end points are 1. The incidence and severity of solicited adverse events on days 0-7 after inoculation with SCTV01E. 2. IgG total antibody concentrations (ELISA) against SARS-CoV-2 prototype strains and neutralizing antibodies titer (Live virus neutraliztion antibody test) against SARS-CoV-2 Omicron variant at 28 days post-vaccination.

NCT ID: NCT05652530 Recruiting - Multiple Myeloma Clinical Trials

Clinical Study of the Safety and Efficacy of BCMA CAR-NK

Start date: November 13, 2022
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to study of the Safety and Efficacy of Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) in Patients with Relapsed/Refractory Multiple Myeloma Primary Endpoints: To evaluate the safety and tolerability of patients with relapsed/refractory multiple myeloma (RR/MM) after BCMA CAR-NK infusion. To determine the maximum tolerated dose (MTD) and/or subsequent recommended dose (RD) of BCMA CAR-NK in patients with RR/MM. Secondary Endpoints: To preliminarily evaluate the effectiveness of BCMA CAR-NK in patients with RR/MM. To preliminarily evaluate the pharmacokinetic parameters of BCMA CAR-NK cells in patients with RR/MM. To preliminarily evaluate BCMA CAR-NK cell survival in subjects blood in relation to efficacy, adverse events and relevant biomarker levels. To preliminarily evaluate the relationship between donors and subjects KIR-Ligand mismatch and safety & efficacy. To preliminarily evaluate the impact of the degree of HLA genotype matching between donors and subjects on the survival of BCMA CAR-NK cells in the subjects blood. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion and enter the follow-up period after the end of the DLT observation period.

NCT ID: NCT05652517 Recruiting - Clinical trials for Persistent Atrial Fibrillation

Univu-guided Vein of Marshall Ethanol Infusion (Marshall-Merge)

Start date: December 2022
Phase: N/A
Study type: Interventional

The study is a prospective, randomized, single-blind clinical trial aiming to compare two method in guidance of Vein of Marshall ethanol infusion (VOMEI), i.e., the conventional fluoroscopy-guided VOMEI and UNIVU-guided VOMEI.

NCT ID: NCT05652283 Active, not recruiting - Ovarian Cancer Clinical Trials

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Start date: November 6, 2022
Phase: Phase 2
Study type: Interventional

The goal of this type of clinical trial study is to evaluate the safety and efficacy of Pamiparib combined with Surufatinib as a new neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer.

NCT ID: NCT05652192 Recruiting - Clinical trials for Advanced Nasopharyngeal Carcinoma

SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC

Start date: September 15, 2022
Phase: Phase 2
Study type: Interventional

Radiotherapy and immunotherapy have achieved good survival benefit in advanced nasopharyngeal carcinoma. A number of clinical studies of immunotherapy combined with radiotherapy for nasopharyngeal carcinoma are also ongoing. This study preliminarily explored the efficacy and safety of SBRT combined with tislelizumab and chemotherapy in metastatic nasopharyngeal carcinoma. Hypofractionated radiotherapy combine with systemic chemotherapy and immunotherapy in advanced nasopharyngeal carcinoma. Not only it can achieve rapid response of distant metastases, but also to achieve long-term survival benefit for patients, which provides the reference for subsequent studies.

NCT ID: NCT05652179 Completed - Clinical trials for Stellate Ganglion Block

SGB Reduces the Incidence and Severity of CSA-AKI

Start date: January 10, 2023
Phase: N/A
Study type: Interventional

The incidence of acute kidney injury after cardiopulmonary bypass cardiac surgery is high, which increases postoperative mortality and is not conducive to the prognosis of patients. Stellate ganglion blocks increase renal blood flow, reduce inflammation and stress, and protect the heart muscle. In this study, stellate ganglion block was used to promote rapid recovery of kidney function after cardiopulmonary bypass cardiac surgery.

NCT ID: NCT05652062 Recruiting - Clinical trials for Failing Bioprosthetic Valve

Prizvalve® Transcatheter Valve-in-Valve Implantation Exploratory Study

Start date: June 2, 2022
Phase: N/A
Study type: Interventional

The primary purpose of this clinical trial is to evaluate the efficacy and safety of the transcatheter aortic valve system in the treatment of patients with failing bioprosthetic valve

NCT ID: NCT05652049 Not yet recruiting - Clinical trials for Peritoneal Sclerosis

Using New Ultrasound Techniques to Assess Peritoneal Fibrosis in Peritoneal Dialysis Patients

Start date: January 1, 2023
Phase:
Study type: Observational

Explore the role of new ultrasound techniques in the assessment of peritoneal fibrosis and encapsulating peritoneal sclerosis in peritoneal dialysis patients

NCT ID: NCT05651971 Recruiting - Rectal Cancer Clinical Trials

The Anatomical Localization of the Inferior Mesenteric Artery in Relation to the Left Colonic Artery

Start date: November 1, 2022
Phase:
Study type: Observational

1. To observe and measure the distance between the origin of LCA (left colonic artery,LCA) and IMA (inferior mesenteric artery,IMA) root and the distance between IMA and IMV (inferior mesenteric vein,IMV) at the origin of LCA in rectal cancer patients. Statistical analysis of intraoperative measured data, on the basis of the original anatomical relationship, to achieve anatomical localization of quantitative and accurate, for the preservation of LCA laparoscopic radical resection of rectal cancer to provide a strong anatomical basis. 2. The operation time, 253 lymph node dissection time, intraoperative blood loss, postoperative anal exhaust time, postoperative feeding time, postoperative hospital stay, postoperative ischemic colitis rate and postoperative anastomotic leakage rate of patients with laparoscopic radical resection of rectal cancer with preservation of LCA were recorded. The surgical efficacy and clinical significance of laparoscopic radical resection of rectal cancer with preservation of LCA were evaluated.

NCT ID: NCT05651893 Recruiting - Colon Adenoma Clinical Trials

Efficacy of Second Forward-view Examination of Left Colon for Adenoma Detection During Colonoscopy

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The incidence of colorectal cancer in China is increasing year by year. Studies have shown that colorectal cancer is more common in the left colon,especially in the China. Our previous study also showed a higher rate of missed adenoma in the left colon than the right colon during colonoscopy. Additionally, prolonging withdrawal time could only improve the ADR of right colon, but had limited effect on the ADR of left colon in our previous research. Our aim is to evaluate the effect of a second forward view examination of the left colon on the detection of adenoma detection during colonoscopy.